Completed

Vitamin C Supplementation for Systemic Lupus Erythematosus

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Vitamin C

+ Placebo

Dietary Supplement
Who is being recruted

Autoimmune Diseases+2

+ Connective Tissue Diseases

+ Immune System Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: September 2024
See protocol details

Summary

Principal SponsorUniversitas Sriwijaya
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2024

Actual date on which the first participant was enrolled.

This study aims to investigate whether taking Vitamin C can help reduce inflammation and improve symptoms in people with a condition called Systemic Lupus Erythematosus (SLE), which is an autoimmune disease affecting multiple parts of the body. The research focuses on patients with mild to moderate lupus activity and seeks to understand if Vitamin C can lower levels of a specific inflammation marker called IL-6 in the blood and improve disease activity. By exploring this, the study hopes to find a simple treatment option that might help manage lupus symptoms and improve patients' quality of life. Participants in the study are divided into two groups. One group receives Vitamin C supplements, while the other group takes a placebo, which is a harmless pill that has no effect. Both groups take their assigned pills twice a day for eight weeks. The researchers measure the level of IL-6 in the blood and assess lupus disease activity using a score called MEX-SLEDAI before and after the treatment. This helps determine if there is any noticeable change in inflammation and disease symptoms due to Vitamin C supplementation. The study is double-blind, meaning neither the participants nor the researchers know who receives the real supplement or the placebo during the trial, ensuring unbiased results.

Official TitleThe Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosus Patients
NCT07071220
Principal SponsorUniversitas Sriwijaya
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

38 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Autoimmune DiseasesConnective Tissue DiseasesImmune System DiseasesLupus Erythematosus, SystemicSkin and Connective Tissue Diseases

Criteria

Inclusion Criteria: 1. All patients diagnosed with systemic lupus erythematosus with mild-moderate disease activity who are treated at the Allergy-Immunology Department of RSMH. 2. Patients aged over 18 years. 3. Willing to participate in the study by signing an informed consent form. Exclusion Criteria 1. Patients with other immune disorders, both autoimmune and immunocompromised conditions such as human immunodeficiency virus (HIV) 2. Pregnant and breastfeeding patients. 3. Patients with malignancies. 4. Patients with chronic liver disorders. 5. Patients with infectious diseases. 6. Patients who consume supplements containing vitamin C. Drop-out Criteria 1. Patients who discontinue vitamin C for more than 3 weeks. 2. Death. 3. Development of serious drug side effects, requiring discontinuation of the medication. 4. Patients who are readmitted or experience symptom deterioration during the intervention period. 5. Loss to follow-up.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
The patients were given a tablet containing Vitamin C 500 mg twice a day

Group II

Placebo
The patients were given a placebo capsule with a similar color, shape, size and taste twice a day

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Mohammad Hoesin General Hospital

Palembang, IndonesiaOpen Mohammad Hoesin General Hospital in Google Maps
CompletedOne Study Center